Stocks News

LAST PRICE
57.5400
TODAY'S CHANGE (%)
Trending Up1.6200 (2.8970%)

Bid / Lots
56.4700/ 1
Ask / Lots
58.2900/ 3
Open / Previous Close
56.2000 / 55.9200
Day Range
Low 56.1400
High 57.7050
52 Week Range
Low 20.8400
High 61.6630
Volume
671,381
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Oct 31, 2024
- DJ Corcept Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 7:28AM ET on Thursday Oct 31, 2024 by Dow Jones
  7:28AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: CORT
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 31, 2024 07:28 ET (11:28 GMT)
Oct 30, 2024
- -- Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Posts Q3 EPS $0.41, from 4:37PM ET on Wednesday Oct 30, 2024 by MT Newswires
  4:37PM ET on Wednesday Oct 30, 2024 by MT Newswires
  Companies Mentioned: CORT
  04:37 PM EDT, 10/30/2024 (MT Newswires) -- ...
- Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: CORT
  
  "Relacorilant has the potential to become the standard of care for patients with platinum-resistant ovarian cancer. If ROSELLA replicates the positive results of our large, controlled, Phase 2 study, it will constitute a major medical advance and serve as the basis for relacorilant's next NDA. We expect progression-free survival data, ROSELLA's primary endpoint, by the end of this year," said Dr. Guyer.
- *DJ Corcept Therapeutics 3Q EPS 41c >CORT, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: CORT
  
  "Relacorilant has the potential to become the standard of care for patients with platinum-resistant ovarian cancer. If ROSELLA replicates the positive results of our large, controlled, Phase 2 study, it will constitute a major medical advance and serve as the basis for relacorilant's next NDA. We expect progression-free survival data, ROSELLA's primary endpoint, by the end of this year," said Dr. Guyer.
Oct 23, 2024
- Press Release: Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call, from 5:11PM ET on Wednesday Oct 23, 2024 by Dow Jones
  5:11PM ET on Wednesday Oct 23, 2024 by Dow Jones
  Companies Mentioned: CORT
  
  Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
  REDWOOD CITY, Calif.--(BUSINESS WIRE)--October 23, 2024--
  Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on October 30, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Today
- DJ Amphastar Pharmaceuticals Initiated at Overweight by Wells Fargo, from 7 hours ago by Dow Jones
  7 hours ago by Dow Jones
  Companies Mentioned: AMPH
- Hutchmed to Receive Milestone Payment for Takeda's Fruzaqla Launch in Japan, from 12 hours ago by MT Newswires
  12 hours ago by MT Newswires
  Companies Mentioned: TAK, HCM
Yesterday
- HUTCHMED Announces Launch by Takeda of FRUZAQLA(R) (fruquintinib) in Japan, from 17 hours ago by GlobeNewswire
  17 hours ago by GlobeNewswire
  Companies Mentioned: TAK, HCM
- HUTCHMED Announces Launch by Takeda of FRUZAQLA(R) (fruquintinib) in Japan, from 17 hours ago by Dow Jones
  17 hours ago by Dow Jones
  Companies Mentioned: TAK, HCM
- ATTENTION Harmony Biosciences Holdings, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights, from 2:07PM ET on Thursday Nov 21, 2024 by Accesswire
  2:07PM ET on Thursday Nov 21, 2024 by Accesswire
  Companies Mentioned: HRMY
- HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES, from 8:05AM ET on Thursday Nov 21, 2024 by PR Newswire
  8:05AM ET on Thursday Nov 21, 2024 by PR Newswire
  Companies Mentioned: HRMY
- HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES, from 8:05AM ET on Thursday Nov 21, 2024 by Dow Jones
  8:05AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: HRMY
- ATTENTION Harmony Biosciences Holdings, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights, from 7:25AM ET on Thursday Nov 21, 2024 by Dow Jones
  7:25AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: HRMY
Nov 20, 2024
- Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY, from 7:31AM ET on Wednesday Nov 20, 2024 by Dow Jones
  7:31AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: HRMY
- Press Release: HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee, from 4:30AM ET on Wednesday Nov 20, 2024 by Dow Jones
  4:30AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: HCM

Corcept Therapeutics Inc
NASDAQ:CORTUnited States

Search Criteria

Oct 31, 2024

DJ Corcept Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 7:28AM ET on Thursday Oct 31, 2024 by Dow Jones

Oct 30, 2024

-- Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Posts Q3 EPS $0.41, from 4:37PM ET on Wednesday Oct 30, 2024 by MT Newswires

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones

*DJ Corcept Therapeutics 3Q EPS 41c >CORT, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones

Oct 23, 2024

Press Release: Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call, from 5:11PM ET on Wednesday Oct 23, 2024 by Dow Jones

Peers Headlines

Today

DJ Amphastar Pharmaceuticals Initiated at Overweight by Wells Fargo, from 7 hours ago by Dow Jones

Hutchmed to Receive Milestone Payment for Takeda's Fruzaqla Launch in Japan, from 12 hours ago by MT Newswires

Yesterday

HUTCHMED Announces Launch by Takeda of FRUZAQLA(R) (fruquintinib) in Japan, from 17 hours ago by GlobeNewswire

HUTCHMED Announces Launch by Takeda of FRUZAQLA(R) (fruquintinib) in Japan, from 17 hours ago by Dow Jones

ATTENTION Harmony Biosciences Holdings, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights, from 2:07PM ET on Thursday Nov 21, 2024 by Accesswire

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES, from 8:05AM ET on Thursday Nov 21, 2024 by PR Newswire

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES, from 8:05AM ET on Thursday Nov 21, 2024 by Dow Jones

ATTENTION Harmony Biosciences Holdings, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights, from 7:25AM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 20, 2024

Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY, from 7:31AM ET on Wednesday Nov 20, 2024 by Dow Jones

Press Release: HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee, from 4:30AM ET on Wednesday Nov 20, 2024 by Dow Jones